The prevalence of metabolic risk factors among outpatients with diagnosed nonalcoholic fatty liver disease in Lithuania

Medical Science Monitor

Volumn 18, Issue 5, 2012, Pages

  Valantinas, Jonas ^a   Apanaviciene, Daiva Asta ^b   Maroziene, Ligita ^c   Sveikata, Audrius ^d  

^a VILNIUS UNIVERSITY   (Lithuania)

^b Sanofi Aventis Lietuva UAB   (Lithuania)

^c CRO Biomapas   (Lithuania)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Cytoprotective drugs; Dyslipidemia; Epidemiology; Metabolic syndrome; NAFLD; Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA CAROTENE; BETAINE; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE; SELENIUM; URSODEOXYCHOLIC ACID;

ABDOMINAL OBESITY; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; DIABETES MELLITUS; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; LEISURE; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OUTPATIENT; PHYSICAL ACTIVITY; PREVALENCE; SEX DIFFERENCE;

EID: 84860654523     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882722     Document Type: Article

References (28)

1. Kim HJ, Kim HJ, Lee KE et al: Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med, 2004; 164: 2169-75
2. Lall CG, Aisen AM, Bansal N, Sandrasegaran K: Nonalcoholic fatty liver disease. Am J Roentgenol, 2008; 190: 993-1002
3. Choudhury J, Sanyal AJ: Clinical aspects of fatty liver disease. Semin Liver Dis, 2004; 24: 349-62
4. Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis, 2008; 28: 339-50
5. Bedogni G, Miglioli L, Masutti F et al: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005; 42: 44-52
6. Akbar DH, Kawther AH: Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit, 2006; 12(1): RA23-RA26
7. Marchesini G, Brizi M, Bianchi G et al: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001; 50: 1844-50
8. Rector RS, Thyfault JP, Wei Y, Ibdah JA: Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol, 2008; 14: 185-92
9. Marchesini G, Bugianesi E, Forlani G et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003; 37: 917-23
10. Marceau P, Biron S, Hould FS et al: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab, 1999; 84: 1513-17
11. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2005; 48: 1684-99
12. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care, 2005; 28: 1769-78
13. Simmons RK, Alberti KG, Gale EA et al: The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010; 53: 600-5
14. Stolar M: Metabolic syndrome: controversial but useful. Cleve Clin J Med, 2007; 74: 199-202, 205-8
15. Gustiene O, Slapikas R, Klumbiene J et al: Metabolinio sindromo paplitimas tarp vidutinio amžiaus Kauno gyventojua{ogonek};. [The prevalence of metabolic syndrome in middle-aged in Kaunas population]. Medicina (Kaunas), 2005; 41: 867-76
16. Cerniauskiene LR, Reklaitiene R, Luksiene DI et al: Metabolinio sindromo ryšys su išemine širdies liga tarp vidutinio amžiaus Kauno gyventojua{ogonek};. (Association of metabolic syndrome with ischemic heart disease among middle-aged Kaunas population). Medicina (Kaunas), 2005; 41: 435-41
17. Paunksnis A, Bojarskiene F, Cimbalas A et al: Relation between cataract and metabolic syndrome and its components. Eur J Ophthalmol, 2007; 17: 605-14
18. Loria P, Adinolfi LE, Bellentani S et al: Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis, 2010; 42: 272-82
19. Fan JG, Jia JD, Li YM et al: Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis, 2011; 12: 38-44
20. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G: Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician, 2007; 53: 857-63
21. Bahcecioglu IH, Koruk M, Yilmaz O et al: Demographic and clinicopathological characteristics of nonalcoholic fatty liver disease in the east-southeastern Anatolia regions in Turkey. Med Princ Pract, 2006; 15: 62-68
22. Loguercio C, De Girolamo V, de Sio I et al: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol, 2001; 35: 568-74
23. Weston SR, Leyden W, Murphy R et al: Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology, 2005; 41: 372-79
24. Malnick SD, Beergabel M, Knobler H: Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM, 2003; 96: 699-709
25. Zaliunas R, Slapikas R, Babarskiene R et al: The prevalence of the metabolic syndrome components and their combinations in men and women with acute ischemic syndromes. Medicina (Kaunas), 2008; 44: 521-28
26. Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. CMAJ, 2005; 172: 899-905
27. Abel T, Fehér J, Dinya E et al: Safety and efficacy of combined ezetimibe/ simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit, 2009; 15(12): MS6-MS11
28. Duvnjak M, Lerotić I, Barsić N et al: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol, 2007; 13: 4539-50